HER2 pos. Disease Supportive care Hans Wildiers University Hospitals Leuven.

HER2 pos. Disease

Supportive care

Hans WildiersUniversity Hospitals Leuven

• HER2 pos. Disease– Adjuvant Trastuzumab:

• HERA (2y vs 1y)• Phare (6 mo vs 1y)• NSABP B-31 and NCCTG N9831 (1y vs nil)

– Metastatic Pertuzumab: Cleopatra – HER2 Translational

• Supportive care– MDS/AML after breast cancer– Neurocognitive impact of adjuvant chemotherapy– Bone

OBSERVATIONn=1698

Women with locally determined HER2-positive invasive early breast cancer

Surgery + (neo)adjuvant CT ± RT

Centrally confirmed IHC 3+ or FISH+ and LVEF ≥ 55%

Randomization

1 year Trastuzumab8 mg/kg – 6 mg/kg3 weekly schedule

n=1703

2 years Trastuzumab8 mg/kg – 6 mg/kg3 weekly schedule

n=1701

After ASCO 2005, option of switch to Trastuzumab

HERA TRIAL UPDATE at 8 y FUP Accrual 2001 – 2005 (n=5102)

CT, chemotherapy; RT, radiotherapy

S5-2

Final analysis planned for 725 disease-free survival (DFS) events to obtain 80% power to detect a true hazard ratio of 0.80.

HER2 adjuvant

Dis

ease

-fre

e su

rviv

al (

%)

Years from randomization

89.1%

86.7%81.0%

81.6%75.8%

76.0%

DFS FOR 2 YEARS VS. 1 YEAR TRASTUZUMAB AT 8 YRS MFU

100

80

60

40

20

00 1 2 3 4 5 6 7 8 9

No. at risk

Trastuzumab 2 years 1553 1553 1442 1361 1292 1223 1153 1051 633 194

Trastuzumab 1 year 1552 1552 1413 1319 1265 1214 1180 1071 649 205

Trastuzumab 1 year

Trastuzumab 2 years

Pts Events HR (2 vs 1) 95% CI p-value

2 years 1553 367 0.99 (0.85-1.14) 0.86

1 year 1552 367

S5-2HER2 adjuvant

Hormone receptor negative2.8% received endocrine therapy

Hormone receptor positive92.6% received endocrine therapy


Dis

ea

se

-fre

e s

urv

iva

l (%

)

Trastuzumab 2 years

Trastuzumab 1 year

DFS BY HORMONE RECEPTOR STATUS AT 8 YRS MFU

No. at risk



100

80

60

40

20

0

0 1 2 3 4 5 6 7 8 9


2 years 798 185 1.05 (0.85-1.29) 0.67

1 year 790 175

90.3%

89.6%

83.1%

82.9%

76.1%

77.2%


Dis

ea

se

-fre

e s

urv

iva

l (%

)

Trastuzumab 2 years

Trastuzumab 1 year

100

80

60

40

20

0

0 1 2 3 4 5 6 7 8 9


2 years 755 182 0.93 (0.76-1.14) 0.51

1 year 762 192

No. at risk



87.8%

83.8%

80.1%

78.9%

75.4%

74.7%

S5-2HER2 adjuvant

Ove

rall

Su

rviv

al (

%)

Years from randomizationNo. at risk



100

80

60

40

20

00 1 2 3 4 5 6 7 8 9

OS FOR 2 YEARS VS. 1 YEAR TRASTUZUMAB AT 8 YRS MFU

97.4%

96.5%91.4%

92.6%86.4%

87.6%

Trastuzumab 1 year

Trastuzumab 2 years


2 years 1553 196 1.05 (0.86-1.28) 0.63

1 year 1552 186

S5-2HER2 adjuvant

Observation Trastuzumab Trastuzumab

Only 1 Year 2 Years

N=1744 N=1682 N=1673

≥ 1 grade 3 or 4 AE 8.2% 16.3% 20.4%

Secondary Cardiac1 0.9% 4.1% 7.2%

Primary Cardiac2 0.1% 0.8% 1.0%

Fatal adverse event 0.4% 1.1% 1.2%

ADVERSE EVENTS(SAFETY ANALYSIS POPULATION)

1 LVEF < 50% and ≥ 10% below baseline confirmed by repeat assessment, excluding patients with a primary cardiac endpoint.

2NYHA class III or IV, confirmed by a cardiologist, and LVEF < 50% and ≥ 10% below baseline, OR cardiac death.

S5-2HER2 adjuvant

Median follow-up(% follow-up time

after selective crossover)

No. of DFS events1 year trastuzumab

vs observation

127 vs 220P<0.0001

218 vs 321P<0.0001

369 vs 458P<0.0001

DFS benefit

Favours 1 year trastuzumab Favours observation0 1 2

HR (95% CI)

1 YEAR TRASTUZUMAB VS. OBSERVATION: DFS ITT ANALYSES

Extended from Gianni et al. Lancet Oncol. 2011.

2005(0%)

2006(4.3%)

2008(33.8%)

1 yr MFU

4 yrs MFU

2 yrs MFU

0.54

0.64

0.76

471 vs 570P<0.0001

2012(48.6%)

8 yrs MFU

0.76

S5-2HER2 adjuvant

Favours 1 year trastuzumab Favours observation0 1 2

HR (95% CI)

OS benefit

1 YEAR TRASTUZUMAB VS. OBSERVATION:OS ITT ANALYSES

Extended from Gianni et al. Lancet Oncol. 2011.

Median follow-up(% follow-up time

after selective crossover)

No. of deaths1 year trastuzumab

vs observation

29 vs 37P=0.26

59 vs 90P=0.0115

182 vs 213P=0.1087

2005(0%)

2006(4.1%)

2008(30.9%)

0.76

0.66

0.85

1 yr MFU

4 yrs MFU

2 yrs MFU

278 vs 350P=0.0005

2012(45.5%)

0.768 yrs MFU

S5-2HER2 adjuvant

PHARE* Trial results of subset analysis comparing 6 to 12 months of trastuzumab in

adjuvant early breast cancer

Protocol of Herceptin®

Adjuvant withReduced Exposure

*lighthouse in French

Xavier Pivot, Gilles Romieu, Marc Debled, Jean-Yves Pierga, Pierre Kerbrat, Thomas Bachelot, Alain Lortholary, Marc Espié, Pierre Fumoleau, Daniel

Serin, Jean-Philippe Jacquin, Christelle Jouannaud, Maria Rios, Sophie Abadie-

Lacourtoisie, Nicole Tubiana-Mathieu, Laurent Cany, Stéphanie Catala, David Khayat,

Iris Pauporté, Andrew Kramar.

S5-3HER2 adjuvant

Study design

trastuzumab 6 months

trastuzumab up to 12 months

stop trastuzumab

Clinical examLVEF

3

Mammography

6 9 12 15 18 21 24 30 mos

…

0

R

R: Randomization after informed consent

Up to 60 mos…

Stratification1. ER pos / neg2. Chemo: conco/

seq

S5-3HER2 adjuvant

Statistical Methods

• Non inferiority randomized trial– 2% variation in terms of absolute difference of

recurrence– The 95% CI HR margins should not cross the 1.15

boundary– 1040 DFS events required for 80% power at 5% level

or4 years of accrual and at least 2 years of follow-up

– HR were estimated from the stratified Cox model

• Accrual target: 3400 patients

S5-3HER2 adjuvant

Treatment Characteristics

12 monthsn=1690

6 monthsn=1690

Type of Chemotherapy No AnthracyclinesAnthracyclines no

taxanesAnthracyclines

and Taxanes

10.2%15.9%73.9%

11.8%15.5%72.7%

Concomitant ChemotherapySequential Chemotherapy

57.8%42.2%

57.7%42.3%

Radiotherapy 87.7% 88.2%

Hormonotherapy 50.6% 50.2%

Trastuzumab duration, mean (sd) 11.8 (2.03) 6.3 (1.46)

S5-3HER2 adjuvant

DFS Events

12 mos(n=1690)

6 mos(n=1690)

DFS Events (n=394) 10.4% 13.0%

Local RecurrenceRegional RecurrenceDistant Recurrence

Controlateral Breast Cancer2nd Primary Malignancy

Death

1.1%0.6%6.4%

0.4%1.5%

0.4%

1.4%0.5%8.3%

0.7%1.5%

0.5%

42.5mos. median Follow-up

S5-3HER2 adjuvant

0.00

0.25

0.50

0.75

1.00D

FS P

roba

bilit

y

1690 1586 1353 939 526 23T-6m1690 1613 1390 980 544 18T-12m

Trastuzumab

0 12 24 36 48 60Months

T-12m T-6m

HR (95% CI): 1.28 (1.05 - 1.56)

Disease Free Survival

* Cox model stratified by ER status and concomitant chemotherapy

95.5 91.2 87.8 84.9

97.0 93.8 90.7 87.8

Events HR 95%CI p-valueT 12m 176T 6m 219 1.28 (1.05 – 1.56) 0.29

S5-3HER2 adjuvant

Equivalent

Superior

Non Inferior

Inferior

A

B

C

D

E

.85 1 1.15 1.3 1.45 1.6

HR

Primary endpoint scenarios

PHARE trial

X Pivot et al, ESMO 2012, LBA5_PR

S5-3HER2 adjuvant

SubanalysisHR (95% CI)

ER and Chemotherapy modalities

1.57 (1.08 - 2.28)

1.25 (0.81 - 1.91)

1.10 (0.73 - 1.65)

1.23 (0.83 - 1.82)

1.28 (1.05 - 1.56)

ER - Sequential (676)

ER + Sequential (850)

ER - Concomitant (786)

ER + Concomitant (1118)

All patients (3380)

0 1.15 2 Favors 6 months Favors 12 months

S5-3HER2 adjuvant

Trastuzumab plus Adjuvant Chemotherapy for HER2-positive Breast Cancer:

Final Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831

San Antonio Breast Cancer Symposium – December 4-8, 2012 Abstract #S5-5

S5-5

Median follow-up: 8.4 years

Definitive survival analysis at 710 OS events

HER2 adjuvant

N9831/B-31 Disease-Free Survival

A P

AC P+H

N EventsAC→P 2018 680AC→P+H 2028 473

HRadj=0.60 (95% CI: 0.53-0.68) P<0.0001

62.2%

73.7%

64.9%

76.8%81.4%

San Antonio Breast Cancer Symposium, December 4-8, 2012S5-5HER2 adjuvant

B-31/N9831 Overall Survival

AC P87.0%

89.8%

79.4%84.3%

N EventsAC→P 2018 418AC→P+H 2028 286

90.3%

∆=2.9% ∆=5.5% ∆=7.6% ∆=8.8%

San Antonio Breast Cancer Symposium, December 4-8, 2012S5-5HER2 adjuvant

1. Baselga J, et al. SABCS 2011 (Abstract S5-5);2. Baselga J, et al. N Engl J Med 2012; 366: 109–119.

CLEOPATRA: update

* < 6 cycles allowed for unacceptable toxicity or PD; > 6 cycles allowed at investigator discretionHER2, human epidermal growth factor receptor 2; PD, progressive disease

Patients withHER2-positive MBCCentrally confirmed

(N = 808)

Placebo + trastuzumabn = 406

• Primary endpoint: Independently-assessed progression-free survival (PFS)

• Collection of tumor tissue (archival in >90%) and serum samples was mandatory

• Study dosing q3w:− Pertuzumab/placebo: 840 mg loading dose, 420 mg maintenance− Trastuzumab: 8 mg/kg loading dose, 6 mg/kg maintenance− Docetaxel: 75 mg/m2, escalating to 100 mg/m2 if tolerated

1:1

n = 402

Docetaxel*≥ 6 cycles recommended

PD

Pertuzumab + trastuzumab

Docetaxel*≥ 6 cycles recommended

PD

P5-18-26HER2 metastatic

CLEOPATRA: overall survival

22Stopping boundary for concluding statistical significance at this second interim analysis was p≤0.0138D, docetaxel; Pla, placebo; Ptz, pertuzumab; T, trastuzumab

0 5 10 15 20 25 30 35 40

0

10

20

30

40

50

60

70

80

90

100

n at risk

0Ptz + T + D

0Pla + T + D

Time (months)

Ove

rall

surv

ival

(%

)

45 50 55

0

0

9

4

33

22

84

67

143

128

230

198

317

285

342

324

371

350

387

383

402

406

89%

94%

1 year

2 years

69%

81% 3 years

66%

50%

Ptz + T + D: 113 events; median not reachedPla + T + D: 154 events; median 37.6 months

HR=0.6695% CI 0.52−0.84

p=0.0008


CLEOPATRA: PFS

D, docetaxel; PFS, progression-free survival; Pla, placebo; Ptz, pertuzumab; T, trastuzumab

0 5 10 15 20 25 30 35 40

0

10

20

30

40

50

60

70

80

90

100

Time (months)

Pro

gre

ssio

n-f

ree

surv

ival

(%

)

45 50

0

0

0

0

8

8

34

26

67

42

108

72

178

110

218

148

284

223

341

329

402

406

Ptz + T + D: median 18.7 monthsPla + T + D: median 12.4 months

HR=0.6995% CI 0.58−0.81

∆=6.3 months

n at risk

Ptz + T + D

Pla + T + D


0

10

20

30

40

50

60

70

80

90

100

0 5 10 15 20 25 30 35

Pro

gre

ssio

n-f

ree

surv

ival

(%

)

Time (months)

Ptz + T + D <65 Pla + T + D <65Ptz + T + D ≥65 Pla + T + D ≥65

CLEOPATRA PFS according to age

D, docetaxel; PFS, progression-free survival; Pla, placebo; Ptz, pertuzumab; T, trastuzumab

24


CLEOPATRA PFS according to age:Exposure to docetaxel treatment

<65 years ≥65 years

Placebo+ trastuzumab

+ docetaxel(n=332)

Pertuzumab+ trastuzumab

+ docetaxel(n=346)


+ docetaxel(n=65)


+ docetaxel(n=61)

Median number of cycles administered (range)

8.0 (1−41) 8.0 (1−35) 6.5 (1−26) 6.0 (1−16)

Median dose intensity, mg/m2/week

24.8 24.5 24.8 24.8

Dose escalation to 100 mg/m2,n (%)

53 (16.0) 41 (11.8) 8 (12.3) 7 (11.5)

Dose reduction to <75 mg/m2,n (%)

72 (21.7) 85 (24.6) 17 (26.2) 19 (31.1)

25


CLEOPATRA PFS according to age: Ten most common grade ≥3 adverse events overall

<65 years ≥65 years

n (%)


+ docetaxel(n=332)


+ docetaxel(n=346)


+ docetaxel(n=65)


+ docetaxel(n=61)

Neutropenia 156 (47.0) 174 (50.3) 26 (40.0) 25 (41.0)Leukopenia 51 (15.4) 44 (12.7) 7 (10.8) 6 (9.8)Febrile neutropenia 26 (7.8) 51 (14.7) 4 (6.2) 5 (8.2)Diarrhea 16 (4.8) 23 (6.6) 4 (6.2) 9 (14.8)Anemia 9 (2.7) 10 (2.9) 5 (7.7) 0 (0.0)Fatigue 9 (2.7) 7 (2.0) 4 (6.2) 2 (3.3)Peripheral neuropathy 6 (1.8) 6 (1.7) 1 (1.5) 5 (8.2)LVSD 8 (2.4) 4 (1.2) 3 (4.6) 1 (1.6)Asthenia 4 (1.2) 10 (2.9) 2 (3.1) 0 (0.0)Granulocytopenia 9 (2.7) 4 (1.2) 0 (0.0) 2 (3.3)

26LVSD, left ventricular systolic dysfunction


The HER2 signalling pathway Selection of biomarkers

ER

Nucleus

c-myc

Raf

MEK 1/2

MAPK

Akt

GSK3 BAD

Cell-cycleprogression

PTEN

mTOR

p27

Cyclin D1, E

FKHR

Grb2 Sos

Cell survival

Ras

Shc SosGrb2

PI3K

Cell proliferation

Y

ER

HER2EGFR HER2 HER3IGF1R

YsHER2

HER ligands

(AREG, EGF, TGFα)

NO RESULTS(except HER2)

HER2 translational S5-7

• Neosphere: associaton between pCR and immune biomarkers S6-7

• Lapatinib decreases Ki67 by 27% in HER2 neg tumors in a ‘window of opportunity’ study (mainly if also high HER3 expression) PD07-07

• New techniques for HER2 determination – Next generation sequencing is highly concordant with FISH

for HER2, and uncovers actionable genomic alterations PD02-07

– MPLA PD02-03,

– RNA scope analysis PD02-04

– AQUA: predicts trastuzumab benefit in BCIRG-005/6

PD02-01

HER2 translational

Activating HER2 mutations in HER2 Gene Amplification Negative Breast Cancers

• HER2 mutations predominantly occur in HER2 gene amplification negative patients.

• The majority of HER2 mutations are activating events that cause oncogenic transformation, thus they are highly likely to be driver events in these breast cancers.

• Neratinib is a highly potent, irreversible pan-ErbB tyrosine kinase inhibitor for all of the HER2 mutations (clinical trial has been launched)

HER2 translational S5-6

MDS/AML after BC diagnosis• Previous reports:

– NSABP trials: 0,27% after AC at 8y if RT after lumpectomy or CSF use.

– An “environmental” cancer

AML/MDS S3-5

AML/MDS S3-5

Characteristics of Leukemia cohort

AML/MDS S3-5

Cumulative incidence of Leukemia

Chemo vs no chemo: HR 2,5 p0,007

AML/MDS S3-5

Conclusions

• Adjuvant chemotherapy was associated with a cumulative 10-year incidence of leukemia of ~ 0.5%

• Almost half of the events occurred beyond year 5 • Radiation alone appears to be a risk factor, but may

not add much to patients already treated with chemotherapy

• Leukemia risk was not limited to MDS/AML, and cases of high risk lymphoid leukemia were observed

• This study highlights the challenges of studying infrequent but important clinical events

AML/MDS S3-5

Neurocognitive Impact in Adjuvant Chemotherapy for Breast Cancer Linked to

Fatigue: A Prospective Functional MRI Study

• Prospective non-randomized comparative trial

chemobrain

S6-3

n=28

n=37

n=32

• Frontal Brain Activation by group and time

chemobrain

S6-3

• Neurocognitive alterations in working memory processes and greater fatigue were evident before any adjuvant chemotherapy.

• Pre-adjuvant treatment brain alterations during working memory task predict severity of fatigue post-treatment.

• Greater fatigue across all groups was related to reduced cognitive function over time.

chemobrain S6-3Results and conclusion

Vitamin D, But Not Bone Turnover Markers, Predict Relapse In Women With Early Breast

Cancer: An AZURE Translational Study.

Bone S6-4

And 25HO VitD

Prognostic effectS6-4

only for 25HO VitD

Bone

Predictive effectS6-4

* CTX, PINP : ZOL benefit NOT predicted by higher bone turnover

* 25HO Vit D

Bone

• Population: 157 pts, 92% continued ZOLonly 37% received per label (q3-4w)

• SRE: - SRE rate 0,13 per person year during 18 month study (vs 0,13 in 18 months

before inclusion)- 83% SRE free at 18 months- persistent ZOL therapy per label ≈ lower SRE rate

(HR 0,26 p 0,009)

• Safety: - renal deterioration in 6 pts- No symptomatic hypoCa (but only 16% taking

supplements!)- Acute phase reactions 9,5%- ONJ in 7 pts (4,5%)

LOTUS trial: Prospective study of treatment pattern, effectiveness, and safety of Zoledronic acid (ZOL) beyond 2y:

subgroup analysis of pts with metastatic breast cancer.

S3-13-01Bone

• Neoadj FEC-paclitaxel +/- ZOL. PD07-05

– randomized trial (n= 182)– pCR 14,9 vs 7,9% (p 0,16)

– in postmenopauzal 18,4 vs 5,4% (p 0,15)

• iv ZOL vs po ibandronat PD09-07

– randomized trial (n=1405)– MBC with bone metastases– SRE rate per year lower for ZOL (0,44 vs 0,54, p 0,02)

BisphosphonatesBone

Conclusions HER2• HER2 adjuvant:

– HERA and NSABP B-31/NCCTG N9831 results at 8 yrs FUP show sustained and statistically significant DFS and OS benefit for 1 year trastuzumab versus observation in ITT analyses despite selective crossover. No benefit for extension to 2 years in HERA.

– PHARE failed to show that 6 months of trastuzumab is non inferior to 12 months. Subgroup analysis suggested that

• Sequential modality for ER negative tumors impacted the overall results.

• Results in other groups seemed compatible with non-inferiority hypothesis

– 1 year of trastuzumab remains the standard of care as adjuvant therapy for patients with HER2-positive early breast cancer.

• HER2 metastatic: – Addition of pertuzumab to trastuzumab and docetaxel improves OS

and PFS significantly in HER2-positive first-line without important toxicity aspects.

Conclusions supportive care

• Adjuvant chemotherapy is associated with a cumulative 10-year incidence of leukemia of ~ 0.5%

• Neurocognitive alterations in working memory processes and greater fatigue are present before any adjuvant chemotherapy.

• Low baseline VitD is associated with increased risk of bone and distant recurrence

HER2 pos. Disease Supportive care Hans Wildiers University Hospitals Leuven.

Documents

Transcript of HER2 pos. Disease Supportive care Hans Wildiers University Hospitals Leuven.